Curesponse(קיוריספונס בע~מ)
Tel Aviv-Yafo, Israel
Curesponse delivers precision oncology solutions via its cResponse™ test, a combined Genomic-Functional assay designed to predict cancer treatment efficacy. Utilizing a 3-dimensional tissue culture system, the platform preserves tumor architecture and microenvironment to assess patient biopsy responses against chemotherapy, biologics, and immunotherapies. Targeting oncologists and patients, it provides actionable insights for optimizing treatment plans in solid tumors. Additionally, the technology serves pharmaceutical partners for drug development research, aiming to improve clinical outcomes through personalized medicine strategies before treatment initiation with exceptionally high prediction accuracy rates supporting informed decision making.
Only accessible to MedStartr community members.
Join nowCompany Info
- Founded
- 2017
- Website
- www.curesponse.com
Only accessible to MedStartr community members.
Join nowWhat do you think of Curesponse(קיוריספונס בע~מ)?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.
Only accessible to MedStartr community members.
Join now